Patents by Inventor Xuexiang DU

Xuexiang DU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MUTANT ANTI-CTLA-4 ANTIBODIES WITH IMPROVED IMMUNOTHERAPEUTIC EFFECT BUT ATTENUATED ADVERSE EFFECTS
    Publication number: 20250043003
    Abstract: This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.
    Type: Application
    Filed: September 24, 2024
    Publication date: February 6, 2025
    Inventors: Yang Liu, Pan Zheng, Fei Tang, Mingyue Liu, Martin Devenport, Xuexiang Du, Yan Zhang
  • Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
    Patent number: 12129299
    Abstract: This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: October 29, 2024
    Assignees: OncoC4, Inc., University of Maryland, Baltimore
    Inventors: Yang Liu, Pan Zheng, Fei Tang, Mingyue Liu, Martin Devenport, Xuexiang Du, Yan Zhang
  • CD80 and CD86 Binding Protein Compositions and Uses Thereof
    Publication number: 20220259285
    Abstract: This invention relates to CTLA-4 protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy.
    Type: Application
    Filed: February 22, 2022
    Publication date: August 18, 2022
    Applicants: ONCOC4, INC., CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT, Wei WU, Xuexiang DU, Mingyue LIU, Fei TANG
  • CD80 and CD86 Binding Protein Compositions and Uses Thereof
    Publication number: 20220259286
    Abstract: This invention relates to CTLA-4 protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy.
    Type: Application
    Filed: February 22, 2022
    Publication date: August 18, 2022
    Applicants: ONCOC4, INC., CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT, Wei WU, Xuexiang DU, Mingyue LIU, Fei TANG
  • CD80 and CD86 binding protein compositions and uses thereof
    Patent number: 11261233
    Abstract: This invention relates to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. Specifically, the disclosure provides a CTLA-4 protein comprising a mutant extracellular domain of CTLA-4, wherein the CTLA-4 protein exhibits reduced binding to an anti-CTLA-4 antibody as compared to a wild-type extracellular domain of CTLA-4, wherein the anti-CTLA-4 antibody has anti-cancer immunotherapeutic activity.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: March 1, 2022
    Assignees: ONCOC4, INC., CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Yang Liu, Pan Zheng, Martin Devenport, Wei Wu, Xuexiang Du, Mingyue Liu, Fei Tang
  • METHODS OF SELECTING AND DESIGNING SAFER AND MORE EFFECTIVE ANTI-CTLA-4 ANTIBODIES FOR CANCER THERAPY
    Publication number: 20210047410
    Abstract: The present invention relates to compositions of anti-CTLA-4 antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for the reduction of autoimmune side effects compared to other immunotherapeutic agents.
    Type: Application
    Filed: January 29, 2019
    Publication date: February 18, 2021
    Applicants: Oncolmmune, Inc., Children's Research Institute, Children's National Medical Center
    Inventors: Yang Liu, Pan Zheng, Fei Tang, Mingyue Liu, Martin Devenport, Xuexiang Du, Yan Zhang
  • MUTANT ANTI-CTLA-4 ANTIBODIES WITH IMPROVED IMMUNOTHERAPEUTIC EFFECT BUT ATTENUATED ADVERSE EFFECTS
    Publication number: 20210040212
    Abstract: This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.
    Type: Application
    Filed: January 29, 2019
    Publication date: February 11, 2021
    Applicants: Oncolmmune, Inc., University of Maryland, Baltimore
    Inventors: Yang Liu, Pan Zheng, Fei Tang, Mingyue Liu, Martin Devenport, Xuexiang Du, Yan Zhang
  • CD80 and CD86 Binding Protein Compositions and Uses Thereof
    Publication number: 20190263889
    Abstract: This invention relates to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. Specifically, the disclosure provides a CTLA-4 protein comprising a mutant extracellular domain of CTLA-4, wherein the CTLA-4 protein exhibits reduced binding to an anti-CTLA-4 antibody as compared to a wild-type extracellular domain of CTLA-4, wherein the anti-CTLA-4 antibody has anti-cancer immunotherapeutic activity.
    Type: Application
    Filed: September 19, 2017
    Publication date: August 29, 2019
    Applicants: ONCOIMMUNE, INC., CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT, Wei WU, Xuexiang DU, Mingyue LIU, Fei TANG